SESEN BIO, INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)

Item 2.02 - Results of Operations and Financial Condition.

On January 11, 2021, Sesen Bio, Inc. (the "Company") disclosed in an updated corporate presentation that it had cash, cash equivalents, and restricted cash of approximately $55 million as of December 31, 2020. This amount is preliminary, has not been audited and is subject to change upon completion of the Company's financial statements for the year ended December 31, 2020. Of note, during 2020 the Company strengthened its balance sheet while minimizing dilution, ahead of the potential FDA approval and commercial launch of Vicineum™ in the United States later this year.

The information under this Item 2.02 shall be deemed to be "filed" for the purposes of the Securities Exchange Act of 1934, as amended.

Item 8.01 - Other Events.

On January 11, 2021, the Company posted an updated corporate presentation on its website www.sesenbio.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, expectations regarding the timing of the Company's potential FDA approval and commercial launch of Vicineum in the United States. These forward-looking statements are based on the Company's current expectations and inherently involve significant risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company's most recent annual report on Form 10-K and the Company's quarterly reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in its expectations.

Item 9.01 - Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.       Description

99.1                Sesen Bio, Inc. Corporate Presentation dated January 11, 2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses